Latest news

Adalvo and Jiangsu Hansoh Pharma, a leading R&D-driven pharmaceutical company in China, are pleased to announce that they have entered into an strategic partnership for the commercialization of Fulvestrant pre-filled injection...

Adalvo is the only B2B platform with a real selected boutique approach to portfolio. We are proud to offer products from all the major pharmaceutical domains, oncology being one of...

Adalvo is pleased to announce that following the successful compilation of all necessary requirements, we have submitted our dossier for Enzalutamide, and did proceed for filing via several DCP procedures...

Adalvo is pleased to announce that in light of the most recent General Court decision that revoked data exclusivity protection on Dimethyl Fumarate (Tecfidera®) hard capsules, we have submitted our...

Adalvo is very excited about this unique opportunity with vast orphan market potential

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine hard capsules development which demonstrates Adalvo´s ability to continuously offer first-to-market opportunities to its valued partners.

Adalvo is happy to announce that following the successful compilation of all necessary requirements today we submitted our Solifenacin+Tamsulosin MR Tablet dossier and will proceed via several DCP procedures in...

Here at Adalvo we are committed to being always on target with the aim of achieving great results for our partners and patients.

Adalvo is delighted to announce the completion of an eCTD format dossier on our Pomalidomide hard capsules development.

Adalvo is happy to claim positive pivotal PK result on its Teriflunomide development which will soon be a new addition to our high-value product portfolio to our customers.

We are happy to announce a positive pivotal PK outcome of our Drospirenone + Estradiol development which is our new milestone in creating Adalvo’s mission for a boutique portfolio containing...

As the Holidays are rapidly approaching, we really wanted to take this opportunity to thank you all for your wonderful collaboration and support in what has undoubtedly been a truly...

The Adalvo team have certainly been busy bees this year, driven by their passion for relentless commitment to customers and business partners. Adalvo has been a true success story...

Adalvo is happy to announce that in addition to our earlier reported studies we successfully closed our last bioequivalence trial that was conducted in steady state dosing.

Alvotech and Teva bring together highly complementary capabilities to secure a leading position in the U.S. biosimilar market. The collaboration is one of the broadest partnerships within the U.S. biosimilar...

Adalvo today announced that it has entered into partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex...

Adalvo is delighted to announce successful Fed and Fast Pivotal BE outcome of its Solifenacin + Tamsulosin development which demonstrates Adalvo's ability to continuously offer first-to-market opportunities to its valued...

Adalvo today announces that it has submitted filings for generic dossier applications with the European Medicines Agency, seeking approval to market an Icatibant pre-filled syringe. Based on available information, Adalvo...

New commercialization agreement in Latin America announced with a large, multinational pharmaceutical firm.

Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with...

Global pharmaceutical companies Alvogen and Alvotech have introduced a new corporate identity for its B2B operations – called Adalvo – following rapid growth in this area of business in the...